IntroductionChinese hamster ovary (CHO) cells are the most widely used host for manufacturing complex biopharmaceuticals due to their ability to replicate folding and post‐translational modifications, including glycosylation patterns, found in human proteins. CHO cells also grow robustly in suspension in serum‐free media and have a long history of regulatory approval and an established track record for producing safe, efficacious products. In 1987, the US Food and Drug Administration (FDA) approved the first CHO‐derived recombinant protein, tissue plasminogen activator (t‐PA) for use as a therapeutic. Since this approval, CHO cells have been the clearly preferred choice for commercial production of glycoprotein biologics, ranging from antibodies to hormones to cytokines. In 2016, 5 of the top 10 biopharmaceuticals were produced in CHO cells while 10 out of the 15 biopharmaceuticals approved by the FDA in 2016 were produced in CHO cells, including 3 biosimilars.Correct glycan structures are crucial for potency and control of pharmacokinetic and pharmacodynamic properties of glycoprotein biologics and therapeutic carbohydrates. Protein glycosylation and synthesis of the glycosaminoglycan (GAG) portion of proteoglycans are non‐templated, and thus, significant heterogeneity can arise from organism to organism, cell type to cell type, and even between different culture conditions. While CHO cells produce
Biotechnology Journal – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud